- Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020
-
Obermair A, Beale P, Scott CL, Beshay V, Kichenadasse G, Simcock B, Nicklin J, Lee YC, Cohen P, Meniawy T
- KMID: 2526284
- J Gynecol Oncol.
- 2021 Nov;32(6):e95.
- doi: 10.3802/jgo.2021.32.e95
Epithelial ovarian cancer (EOC) is among the top ten causes of cancer deaths worldwide, and is one of the most lethal gynecological malignancies in high income countries, with incidence and... -
- CITED
-
- Close
- SHARE
-
- Close
- PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression
-
Kok PS, Beale P, O'Connell , Grant P, Bonaventura T, Scurry J, Antill Y, Goh J, Sjoquist K, DeFazio A, Mapagu C, Amant F, Friedlander M, on behalf of the PARAGON Investigators
- KMID: 2457159
- J Gynecol Oncol.
- 2019 Sep;30(5):e86.
- doi: 10.3802/jgo.2019.30.e86
OBJECTIVE: A subset of patients with recurrent ovarian cancer (ROC) may benefit from antiestrogen therapy with higher response rates reported in tumors that are strongly estrogen receptor (ER)-positive (ER+). PARAGON... -
- CITED
-
- Close
- SHARE
-
- Close
